Australian researchers have just completed phase 3 clinical trials of a long-lasting monoclonal antibody treatment called Nirsevimab, which works much like a vaccine.
Australian researchers have just completed phase 3 clinical trials of a long-lasting monoclonal antibody treatment called Nirsevimab, which works much like a vaccine.
Australian researchers have just completed phase 3 clinical trials of a long-lasting monoclonal antibody treatment called Nirsevimab, which works much like a vaccine.
Australian researchers have just completed phase 3 clinical trials of a long-lasting monoclonal antibody treatment called Nirsevimab, which works much like a vaccine.